Infusion of chimeric antigen receptor T cells against dual targets of CD19 and B-cell maturation antigen for the treatment of refractory multiple myeloma

Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells

(2018) Kevin M. Friedman et al.   HUMAN GENE THERAPY

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

(2016) Yongxian Hu et al.   Journal of Hematology & Oncology

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms

(2016) M Ruella et al.   LEUKEMIA

Anti-BCMA CAR T cells show promise in MM

(2016) Peter Sidaway   Nature Reviews Clinical Oncology

Multiple myeloma epidemiology and survival: A unique malignancy

(2016) Dickran Kazandjian   SEMINARS IN ONCOLOGY

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

(2016) D. T. Teachey et al.   Cancer Discovery

ReCAP: Identifying Severe Adverse Event Clusters Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events

(2016) Xiaobo Zhong et al.   Journal of Oncology Practice

Tumor neoantigens: building a framework for personalized cancer immunotherapy

(2015) Matthew M. Gubin et al.   JOURNAL OF CLINICAL INVESTIGATION

Multiple Myeloma, Version 2.2016

(2015) Kenneth C. Anderson et al.   Journal of the National Comprehensive Cancer Network

Multiple myeloma

(2015) Christoph Röllig et al.   LANCET

CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

(2015) S S Kenderian et al.   LEUKEMIA

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

(2015) Alfred L. Garfall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

(2015) Laura A. Johnson et al.   Science Translational Medicine

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management

(2014) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2013) P. Moreau et al.   ANNALS OF ONCOLOGY

Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse

(2013) L. Pour et al.   HAEMATOLOGICA

Cytokine-induced killer cells promote antitumor immunity

(2013) Jingting Jiang et al.   Journal of Translational Medicine

Possible Future Monoclonal Antibody (mAb)-Based Therapy against Arbovirus Infections

(2013) Giuseppe Sautto et al.   Biomed Research International

Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells

(2012) J. Scholler et al.   Science Translational Medicine

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

(2011) C. U. Louis et al.   BLOOD

Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

(2010) John A. Craddock et al.   JOURNAL OF IMMUNOTHERAPY